Most prescription drugs taken in the United States are produced through a global supply chain that spans multiple countries. Nearly two in five finished prescription drug products are made domestically, but the raw ingredients inside those pills tell a different story: only about 10% of the active pharmaceutical ingredients by volume are manufactured in the U.S. The rest come from facilities scattered across India, China, Europe, and other regions.
Where the Ingredients Come From
Every prescription drug has an active pharmaceutical ingredient, or API, which is the compound that actually treats your condition. The pill, capsule, or liquid you receive from the pharmacy is the “finished” product, but the API had to be synthesized somewhere first, often in a completely different country from where the final pill was pressed and packaged.
As of 2019, 72% of the API manufacturing facilities supplying the U.S. market were located overseas. The U.S. had about 510 API facilities (28% of the total), China had roughly 230 (13%), and the remaining 59% were spread across the rest of the world, including India and the European Union. Those numbers have been shifting. By 2024, China’s share of new API manufacturing filings had surged dramatically, nearly tripling from 134 filings in 2021 to 392 in 2024. For the first time in more than two decades, China overtook India in annual filings for new API manufacturing, now accounting for 45% of all new filings in a given year.
India, meanwhile, remains a pharmaceutical powerhouse in its own right. The country supplies roughly 40% of generic drug demand in the United States and 25% of all medicines used in the United Kingdom. It ranks as the world’s third-largest drug producer by volume and handles about 60% of the global supply of low-cost vaccines.
Where Finished Pills and Tablets Are Made
The geography of finished drug manufacturing depends heavily on whether a drug is a brand-name product, a generic, or a biologic (a complex drug made from living cells).
Brand-name drugs and biologics are still primarily manufactured in the United States and Europe. In 2020, about 79% of brand-name drug manufacturing took place in these two regions, down from 89% in 2011. Biologics are even more concentrated: 93% were made in the U.S. or Europe as of 2020, though that figure had been 100% just nine years earlier.
Generic drugs have followed a very different trajectory. India’s share of generic drug manufacturing for the U.S. market jumped from 21% in 2011 to 51% in 2020. Over the same period, U.S.-based generic manufacturing dropped from 52% to 35%. Since generics account for about 90% of all prescriptions filled in America, this shift means the majority of the pills Americans actually take every day are now produced in India.
Europe’s Role in Global Production
Several European countries are major pharmaceutical exporters, particularly for brand-name and specialty drugs. In 2024, Germany was the largest EU exporter of medicinal and pharmaceutical products to countries outside the bloc, shipping €68 billion worth of products. Ireland followed at €56 billion and Belgium at €41 billion. Ireland’s pharmaceutical sector is especially outsized relative to its population: medicinal and pharmaceutical products made up 42% of the country’s total exports outside the EU.
Switzerland, while not an EU member, is home to several of the world’s largest pharmaceutical companies and accounted for 33% of the EU’s pharmaceutical imports in 2024. The United States was both the largest destination for EU drug exports (38% of total) and the largest source of EU drug imports (also 38%).
Why Manufacturing Is So Spread Out
The globalization of drug manufacturing happened over decades, driven by lower production costs in countries like India and China, growing technical expertise in those regions, and the economic pressure on drugmakers to reduce expenses, especially for generic medications where profit margins are thin. A single prescription drug might have its API synthesized in China, shipped to India for formulation into tablets, then packaged and labeled in the U.S. before reaching your pharmacy shelf.
This geographic spread creates real vulnerabilities. Policymakers have flagged several risks tied to concentrated manufacturing: geopolitical conflicts could disrupt supply from a single region, natural disasters could knock out major facilities, and regulatory oversight becomes harder when production sites are thousands of miles from the agencies responsible for inspecting them. The COVID-19 pandemic exposed some of these weaknesses when lockdowns and shipping disruptions temporarily threatened supplies of essential medicines.
How Much the U.S. Actually Makes
The U.S. remains a significant drug manufacturer, but its role varies by product type. For finished prescription products, about 40% are made domestically, including many essential medicines. For APIs, the picture is far more dependent on foreign sources, with only about 10% of API volume produced in the U.S. For the 370 drugs on the World Health Organization’s essential medicines list that are marketed in America, the U.S. houses just 21% of the API facilities, while China has 15% and the remaining 64% are elsewhere around the world.
One complication is that even FDA data can’t fully capture the picture. The agency has acknowledged it cannot calculate the actual volume of APIs coming from China or India, or what percentage of U.S. drug consumption those volumes represent. Facility counts don’t tell you how much each facility produces, so a country with fewer but larger plants could supply a disproportionate share of the market.
Efforts to Bring Manufacturing Back
The concentration of drug production overseas has prompted government action. The U.S. has moved to establish a strategic reserve of active pharmaceutical ingredients, modeled loosely on the concept of the Strategic Petroleum Reserve. The goal is to stockpile critical raw materials domestically so that shortages from overseas disruptions don’t immediately translate into empty pharmacy shelves. There have also been broader calls for “onshoring,” or incentivizing companies to build more manufacturing capacity within the United States, particularly for essential and generic medicines.
Some health policy researchers have recommended that drug labels prominently display where both the API and the finished product were manufactured, giving consumers and healthcare systems more transparency about the origins of their medications. Currently, most people have no practical way to find out where the specific pill in their hand was made.